Histone deacetylase 3 inhibitor ameliorates hypoxia/reoxygenation injury in PC12 cells by reducing oxidative#br#

LEI Lei; LU Xuan; YANG Jin-Song; YOU Yu-Zhen; MEI Yan

doi:10.16098/j.issn.0529-1356.2021.05.006

PDF(2731 KB)

Acta Anatomica Sinica ›› 2021, Vol. 52 ›› Issue (5) : 706-711. DOI: 10.16098/j.issn.0529-1356.2021.05.006

Neurobiology

Histone deacetylase 3 inhibitor ameliorates hypoxia/reoxygenation injury in PC12 cells by reducing oxidative#br#

LEI Lei^1* LU Xuan²YANG Jing-song³ YOU Yu-zhen¹ MEI Yan¹

Author information +

History +

Abstract

Objective To investigate the role of histone deacetylase 3（HDAC3）inhibitor (HDAC3I) in hypoxia-reoxygenation(H/R) injury of PC12 cells. Methods H/R cell injury model was established by using PC12 cells for 4 hours hypoxia and then reoxygenation for 24 hours. HDAC3I treatment group was pretreated with RGFP966 for 1 hour and then subjected to hypoxia-reoxygenation injury. The experiment was divided into three groups: normal control group, model group and HDAC3I treatment group, and 3 repetitions for each group. Cell viability was determined using MTT. Cellulose dehydrogenase (LDH) was detected by colorimetry. Flow cytometry was used to detect apoptosis and intracellular reactive oxygen species (ROS), respectively. The activity of superoxide dismutase (SOD) was determined by xanthine oxidase method . The malondialdehyde (MDA) content was determined by the thiobarbituric acid method . Western blotting was used to detect the expression of Bax, Bcl-2, cleaved-Caspase-3 and HDAC3 proteins. Results Compared with the control group, the cell viability of the model group and HDAC3I treatment group decreased significantly (P<0.05), and the cell LDH (P<0.05) and apoptosis (P<0.05) increased significantly. The cell viability of HDAC3I treatment group was significantly higher than that of the model group (P<0.05), while the LDH (P<0.05) and apoptosis of HDAC3I treatment group were lower than the model group (P<0.05). In addition, compared with the control group, the ROS and MDA (P<0.05) of the model group and the HDAC3I treatment group increased significantly, and the SOD decreased significantly (P<0.05). ROS and MDA in the HDAC3I treatment group (P<0.05) were significantly lower than the model group, while the SOD level was higher than the model group (P<0.05). Western blotting analysis showed that compared with the control group, Bax and cleaved-Caspase-3 in the model group and HDAC3I treatment group increased significantly, and Bcl-2 decreased significantly (P<0.05). The Bax and cleaved-Caspase-3 in the HDAC3I treatment group were significantly lower than the model group, and Bcl-2 was significantly higher than the model group (P<0.05). Compared with the control group, the expression of HDAC3 protein in the model group increased significantly (P<0.05), while the HDAC3 protein in the HDAC3I treatment group decreased significantly (P<0.05). Conclusion HDAC3I reduces PC12 cell apoptosis induced by hypoxia/reoxygenation by reducing oxidative stress.

Key words

Histone deacetylase inhibitor / Oxidative stress response / Hypoxia/reoxygenation / Flow cytometry

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LEI Lei LU Xuan YANG Jing-song YOU Yu-zhen MEI Yan. Histone deacetylase 3 inhibitor ameliorates hypoxia/reoxygenation injury in PC12 cells by reducing oxidative#br#[J]. Acta Anatomica Sinica. 2021, 52(5): 706-711 https://doi.org/10.16098/j.issn.0529-1356.2021.05.006

References

［1］ Wu YJ, Chen ChH. Progress of adjuvant treatment with tissue plasminogen activator beyond time window in ischemic stroke［J］. Acta Anatomica Sinica, 2019,50(6):850-856.(in Chinese)
吴冶君,陈春花.缺血性脑卒中治疗时间窗后辅助溶栓治疗的进展［J］.解剖学报,2019,50(6):850-856.
［2］ Cao DF, Yang N. Structure and catalytic mechanisms of histone deacetylases［J］. Progress in Biochemistry and Biophysics,2015, 42(11):978-993. (in Chinese)
曹端方,杨娜.组蛋白去乙酰化酶的结构及应用［J］.生物化学与生物物理进展,2015,42(11):978-993.
［3］ Yang X, Wu Q, Zhang L, et al. Inhibition of histone deacetylase 3 (HDAC3) mediates ischemic preconditioning and protects cortical neurons against ischemia in rats ［J］. Front Mol Neurosci, 2016,9:131.
［4］ Demyanenko S, Neginskaya M, Berezhnaya E. Expression of class Ⅰ histone Deacetylases in ipsilateral and contralateral hemispheres after the focal photothrombotic infarction in the mouse brain ［J］.Transl Stroke Res, 2018, 9(5):471-483.
［5］ Jiang R, Lü KN, Pan XF, et al. Current status and challenges of epigenetic drug research and development［J］. Biotechnology Bulletin, 2019,35(8):213-225. (in Chinese)
江芮,吕柯孬,潘学峰,等.表观遗传药物研发的现状与挑战［J］.生物技术通报,2019,35(8):213-225.
［6］ Dong ZhJ, Han Ch, Liu JJ, et al. Histone deacetylase inhibitors:research advances［J］. Journal of International Pharmaceutical Research, 2017,44(12):1098-1106, 1124. (in Chinese)
董照记,韩诚,刘晶晶,等.组蛋白去乙酰化酶抑制剂的研究进展［J］.国际药学研究杂志,2017,44(12):1098-1106,1124.
［7］ Li L, Jin J, Yang XJ. Histone deacetylase 3 governs perinatal cerebral development via neural stem and progenitor cells ［J］. iScience, 2019,20:148-167.
［8］ Zhan HY, Tao H, Xu ShS, et al. Role of HDAC3 in H9C2 cell ischemia-reperfusioninjury and intervention mechanism ［J］. Acta Universitatis Medicinalis Anhui, 2017,52(5):674-677. (in Chinese)
占红英,陶辉,徐盛松,等. HDAC3在H9C2细胞缺血再灌注损伤中的表达及干预机制［J］.安徽医科大学学报,2017,52(5):674-677.
［9］ Bardai FH, D’Mello SR. Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta ［J］. J Neurosci, 2011,31(5):1746-1751.
［10］ Zhao QCh, Xu Y. Research progress of histone deacetylase 3 in nervous system diseases ［J］. Journal of International Neurology and Neurosurgery, 2015, 42(4):384-388. (in Chinese)
赵秋宸,徐运.组蛋白去乙酰化酶3在神经系统疾病中的研究进展［J］.国际神经病学神经外科学杂志,2015,42(4):384-388.
［11］ Fan WX. Research progress on the mechanism of ischemic stroke ［J］. Journal of China Pharmaceutical University, 2018, 49(6):751-759. (in Chinese)
樊文香.缺血性脑卒中的机制研究进展［J］.中国药科大学学报,2018,49(6):751-759.
［12］ Chen H, Wu JJ, Xue Q, et al. Progress in research on the mitochondrial mechanism of ischemica stroke and effective components of TCM［J］. Chinese Journal of New Drugs, 2016, 25(11):1236-1240. (in Chinese)
陈红,吴俊杰,薛强,等.以线粒体为靶点抗缺血性脑卒中中药有效成分研究进展［J］.中国新药杂志,2016,25(11):1236-1240.